NCT05029453

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

A Prospective, Multicenter, Randomized Controlled Study of Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is a multicenter, open-label, randomized controlled clinical study. The purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric cancer receiving prior anti-PD-1 therapy.

Detailed description

60 patients who meet the inclusion criteria will receive apatinib combine with chemotherapy or chemotherapy until the disease progresses or intolerable. Apatinib: initial dose: 500mg,oral,once a day, after meal (try to take the medicine at the same time each day)

Conditions

• Gastric Cancer
• Randomized Controlled Study

Interventions

Type	Name	Description
DRUG	Apatinib	In experimental group, the drug used with apatinib and chemotherapy.

Timeline

• Start date: 2021-08-26
• Primary completion: 2022-12-31
• Completion: 2023-03-03
• First posted: 2021-08-31
• Last updated: 2021-08-31

Locations

1 site across 1 country: China